HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q2 2018 13F Holders as of 30 Jun 2018

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
122,773,490
Share change
+258,423
Total reported value
$2,071,287,861
Put/Call ratio
59%
Price per share
$16.87
Number of holders
192
Value change
-$3,330,339
Number of buys
85
Number of sells
100

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2018

As of 30 Jun 2018, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 192 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 122,773,490 shares. The largest 10 holders included Third Security, LLC, VANGUARD GROUP INC, BlackRock Inc., IRIDIAN ASSET MANAGEMENT LLC/CT, BB BIOTECH AG, STATE STREET CORP, Invesco Ltd., JPMORGAN CHASE & CO, PICTET ASSET MANAGEMENT LTD, and FMR LLC. This page lists 193 institutional shareholders reporting positions in this security for the Q2 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.